Whether it is new and groundbreaking research results, university topics or events – in our press releases you can find everything you need to know about the happenings at 51ÁÔÆæ. To subscribe, just send an email to ott@pvw.uni-frankfurt.de
Theodor-W.-Adorno Platz 1
60323 Frankfurt
presse@uni-frankfurt.de
​ The „International Conference on Learning Analytics & Knowledge 2020“ (LAK20) is dedicated to the measurement and analysis of data from technology-based learning processes – registration is still open.
​ 51ÁÔÆæ and University Hospital Frankfurt ask for funding for research, equipment and patient care
FRANKFURT. At least five million euros – this is the sum that 51ÁÔÆæ and the University Hospital want to collect to better meet the challenges of the Corona pandemic. Anyone can help: the money is to be raised through the donation platform betterplace.org and will go primarily toward researching the coronavirus, the urgent training of employees, and patient care at the University Hospital. Direct donations are also possible (please see link and donation account at the end of this press release).
The Johanna Quandt University Foundation made the start: non-bureaucratically, and within 24 hours, it provided a quarter million euros for the corona researcher Professor Sandra Ciesek and her team. With this money, the virologists from 51ÁÔÆæ and University Hospital want to advance their search for effective treatment. But this is only a beginning. The corona crisis requires a substantial degree of additional exertion – and therefore a substantial amount of additional funding.
“Our call goes out to everyone who wants to not just marvel at the incredible challenges, but to provide tangible help: donate to the Goethe-Corona fund. Every contribution is important and welcome," says University President Professor Birgitta Wolff, appealing to people's willingness to help. “If we all want to weather this crisis well and perhaps even emerge from it stronger than before, now is the time to set the course. If the city and university communities close ranks – not physically, of course – we can master even great challenges. This is precisely why the university was founded over 100 years ago," Wolff adds. As Stiftungsuniversität (university foundation under public law), 51ÁÔÆæ has the necessary leeway to also take unorthodox paths to enable financing, says Wolff. In the name of the University, the University Hospital, and the patients affected, she already expresses thanks to everyone who with their donation contributes to an improvement of the situation.
To master the crisis scientifically, clinically and organisationally, Goethe University and the Frankfurt University Hospital require additional personnel in the short term, and financial means. For this reason, the Goethe Corona Fund was established with the intention that it will quickly increase to at least five million euros – with the help of donations from the general public, foundations, and other private sponsors. Toward this end, a donation page was set up on the platform Betterplace; direct transfers are also possible, and both provide a donation receipt. First commitments have already been made from the circle of researchers: a professor has already announced a donation of 40,000 euros.
“The growing pandemic entails a growing financial need in many areas: for example, we need money for specific equipment and experts, training for additional helpers in the crisis, and also to equip our medical personnel with protective clothing, goggles and face masks," says Professor Jürgen Graf, medical director of the University Hospital. In research, particular focus is placed on the patient-oriented research conducted by Professor Sandra Ciesek and her team: the goal is to find a vaccine and medical treatment for the aggressive virus, and to improve the diagnosis procedure. “With the aid of the additional funds we can emphatically expedite this research," explains virologist Ciesek. To do so, employees with biostatistical or biomedical training need to be hired in order to process and analyse the generated clinical data. In addition, additional equipment is urgently needed in virological and intensive care research and development in order to carry out experiments and studies more quickly and efficiently.
But in teaching as well, financial support is urgently needed: students should have the opportunity to participate in training and simulation classes to prepare them for the difficult situations in clinical daily routine. For this, additional medical simulation mannequins are required. “We are quick to reach the limits of our capacity in this area, although there is tremendous interest and commitment on the part of the students," says Professor Josef Pfeilschifter, Dean of the Faculty of Medicine at 51ÁÔÆæ. Teaching, education and training also depend on realistic simulations.
Donations via our donation project on www.betterplace.org:
Or as wire transfer to the donation account:
Landesbank Hessen-Thüringen
IBAN: DE95 5005 0000 0001 0064 10
Purpose: Goethe-Corona-Fonds
Further information: Contact to Prof. Sandra Ciesek through the Frankfurt University Hospital: Christoph Lunkenheimer, University Hospital press officer, telephone: +49 69 6301-86442, christoph.lunkenheimer@kgu.de.
Rhythmic neural signals determine the sounds that bats make
The 2020 Paul Ehrlich and Ludwig Darmstaedter Prize for Young ResearchersÂ
The formation of gametes and the first cell divisions of the fertilized egg in mammals are prone to errors. Sometimes the wrong number of chromosomes is passed on to the offspring, or the first division leads to two nuclei instead of one in the two-cell embryo. In most cases, these errors result in miscarriages. Judith Reichmann has shown what leads to these errors in mouse embryos.
FRANKFURT am MAIN. Today, Dr. Judith Reichmann is receiving the €60,000
Paul Ehrlich and Ludwig Darmstaedter Prize for Young Researchers 2020. Dr.
Reichmann, who works at the European Molecular Biology Laboratory (EMBL) in
Heidelberg, researches the sources of chromosomal abnormalities in eggs and
embryos of mice and their potential contribution to miscarriages. Mice
synthesize a protein called Tex19.1, which maintains chromosome cohesion during
the formation of oocytes and protects sperm cells from genetic damage. Without
this protein, many mouse embryos have the wrong number of chromosomes and die
after a few cell divisions. Errors also occur when the fertilized egg splits
into two daughter cells. Reichmann was able to show that the paternal and
maternal chromosome sets are not passed on via one but two mitotic spindles. As
a result, the two sets of chromosomes sometimes drift apart during the cell
division process so that the two-cell embryo ends up with two haploid cell
nuclei instead of one diploid cell nucleus.
Reichmann discovered the dual spindle formation
using light-sheet microscopy, which she developed further for this purpose.
Mouse embryos do not tolerate continuous light exposure and therefore cannot be
examined with a conventional microscope in high spatiotemporal resolution. This
has precluded detailed live-imaging analyses in the past. In light-sheet microscopy, illumination occurs only in
the plane that is actually being observed, while other parts of the embryo
remain in the dark. "Judith Reichmann has shown how mice make sure that
their offspring have the correct number of chromosomes, and only one cell
nucleus. If this process fails, reproduction is compromised," the
Scientific Council´s statement reads. "Reichmann's research may one day
contribute to reducing the rate of miscarriages in women - provided that the
sources of error identified in mice also apply to human reproduction".
Reichmann discovered that the Tex19.1 protein
indirectly stabilizes the chromosomes during meiosis. This process ensures that
the gametes enter fertilization with a single set of chromosomes, for without
this process the number of chromosomes would double with each generation. In
oocytes, stabilization of the chromosomes is needed because meiosis is
interrupted for a long time and is only completed upon fertilization. When
Tex19.1 is missing, the chromosomes drift apart in the egg. As a result, many
embryos among the offspring do not inherit the correct number of chromosomes.
Reichmann's discovery of the dual spindles during
the first cell division of the fertilized egg has toppled a textbook statement.
Up to now, it had been assumed that the parental chromosomes merge in the
fertilized egg and are distributed to the two daughter cells via a single
spindle apparatus. Reichmann was able to show that the paternal and maternal
chromosomes are grouped separately from each other in two spindles and are then
distributed to the poles. Even in the nucleus of the two-cell embryo, maternal
and paternal chromosomes initially remain in different hemispheres before they
finally mix during subsequent cell divisions.
If Reichmann´s findings in mice also hold for human
embryogenesis, and the human paternal and maternal chromosomes only merge in
the two-cell embryo as well, a central assumption of the German Embryo
Protection Act may have to be reconsidered. It states that human life begins
when maternal and paternal chromosomes join; by this definition, the two-cell
embryo rather than the zygote would take centre stage.
The Paul Ehrlich and Ludwig Darmstaedter Prize for
Young Researchers has been awarded since 2006 in recognition of outstanding achievements
in biomedical research.
Short
biography of Dr. Judith Reichmann
Judith
Reichmann (35) studied applied biology at the University of Applied Sciences
Bonn-Rhein-Sieg. At the end of her studies, she moved to the University of
Aberdeen in Scotland where she pursued a bachelor's degree in genetics. At the
University of Edinburgh, she completed her doctorate on the development of
oocyte and sperm cells. Reichmann came to EMBL as a postdoctoral fellow in 2012
to investigate cell division at the beginning of life using the latest
microscopy techniques. She has been working as a research scientist at EMBL
since 2017. Reichmann is married and has two children.
Paul Ehrlich and Ludwig
Darmstaedter Prize for Young Researchers
The Paul Ehrlich and Ludwig Darmstaedter Prize
for Young Researchers, awarded for the first time in 2006, is conferred once a
year by the Paul Ehrlich Foundation on a young investigator working in Germany
for his or her outstanding achievements in the field of biomedical research.
The prize money must be used for research purposes. University faculty members
and leading scientists at German research institutions are eligible for
nomination. The selection of the prizewinner is made by the Scientific Council
on a proposal by the eight-person selection committee.
The Paul Ehrlich Foundation
The
Paul Ehrlich Foundation is a legally dependent foundation which is managed in a
fiduciary capacity by the Association of Friends and Sponsors of the Goethe
University, Frankfurt. The Honorary Chairman of the Foundation, which was
established by Hedwig Ehrlich in 1929, is Professor Dr. Katja Becker, president
of the German Research Foundation, who also appoints the elected members of the
Scientific Council and the Board of Trustees. The Chairman of the Scientific
Council is Professor Thomas Boehm, Managing Director at the Max Planck
Institute of Immunobiology and Epigenetics in Freiburg, the Chair of the Board
of Trustees is Professor Dr. Jochen Maas, Head of Research and Development and
Member of the Management Board, Sanofi-Aventis Deutschland GmbH. Professor
Wilhelm Bender, in his function as Chair of the Association of Friends and
Sponsors of the 51ÁÔÆæ, is Member of the Scientific Council. The
President of the 51ÁÔÆæ is at the same time a member of the Board of
Trustees.
Further
information
You can obtain selected
publications, the list of publications and a photograph of the prizewinner from
Dr. Hildegard Kaulen, phone: +49 (0) 6122/52718, e-mail:
h.k@kaulen-wissenschaft.de and at .
The 2020 Paul Ehrlich and Ludwig Darmstaedter PrizeÂ
Attack or peacekeeping? Immune cells answer this question countless times a day. If they regularly missed the mark, it would have serious consequences for human health. The regulatory T cells discovered by Shimon Sakaguchi help the immune system to distinguish between friend and foe and are instrumental for achieving self-tolerance. Strengthening or weakening this peacekeeping force gives the immune system a kick or a damper. Both strategies can be harnessed to develop new treatments for human diseases.
FRANKFURT
am MAIN. Tomorrow, Shimon Sakaguchi, professor of
Experimental Immunology at Osaka University (Japan) will receive the 2020 Paul
Ehrlich and Ludwig Darmstaedter Prize for his pioneering discoveries of
regulatory T cells and their role in self-tolerance. These cells have the
potential to become the new heroes of medicine. They keep the immune system in
balance and ensure that it doesn´t run amok or becomes inattentive.
"Without regulatory T cells, the immune system would not be able to
correct errors in distinguishing between friend and foe with the necessary
precision," explained the Scientific Council of the Paul Ehrlich
Foundation when presenting the award. "The immune system needs such
regulatory control, because overreaction leads to autoimmune diseases such as
rheumatoid arthritis and type 1 diabetes, whereas reduced activity gives cancer
cells the opportunity to evade immune attack and eventually establish
metastases. Therefore, Sakaguchi's discovery offers great potential for the
development of new treatments."
Early on in his studies,
Sakaguchi was convinced that an immunological peacekeeping force must exist in
order to establish immune homeostasis. The difficulty he faced was that there
was no molecular marker that would allow him to identify and isolate these
cells. Therefore, Sakaguchi set out to search for such a telltale feature.
After many years of painstaking work, he demonstrated that the surface protein
CD25 is a reliable marker for these cells. "The discovery of CD25 was a
watershed in immunological research. It proved the existence of regulatory
T-cells and pointed a way forward to isolate and characterize them in greater
detail," said Professor Thomas Boehm, Director at the Max Planck Institute
of Immunobiology and Epigenetics in Freiburg, and Chairman of the Scientific
Council. "This seminal discovery has given the field of immune regulation
an enormous boost. Suddenly, many scientists became interested in the biology
and use of regulatory T cells."
Subsequently, Sakaguchi was able to show that Foxp3
is the central on/off switch of regulatory T cells, a finding that was quickly
confirmed by others. This discovery established an unexpected connection
between regulatory T cells and a rare congenital syndrome known as IPEX, which
had been shown to be due to the lack of Foxp3. IPEX patients develop severe
autoimmune diseases shortly after birth, often leading to early death. Thus,
the medical relevance of Sakaguchi´s earlier discovery of regulatory T cells
became obvious: patients with IPEX syndrome suffered from lack of an
immunological peacekeeping force.
Because of their fundamental importance for the
immune system, the manipulation of regulatory T cells offers new forms of
treatment for a wide range of conditions. In the case of autoimmune diseases
such as rheumatoid arthritis, type 1 diabetes and multiple sclerosis, their
activity must be strengthened so that they can take more decisive action
against inappropriate attacks on the body's own tissue. In cancer, the activity
of regulatory T cells needs to be attenuated. Although they no longer adhere to
their normal cellular program, cancer cells are often not considered foreign by
the immune system. Hence, the protection of tumor cells by regulatory T cells
is unfortunate, as this prevents them from being eliminated. Therefore, to
eliminate the tumor´s camouflage, regulatory T cells, which are
disproportionately abundant in tumors, must be either reduced in number or
their activity diminished to allow an efficient attack on the tumor.
Attenuation of regulatory T cell activity, however,
needs to be very precisely controlled, both in space and in time, for they are
needed elsewhere in the body to maintain immune homeostasis. "The
challenge is to manipulate regulatory T cells only at the site of the tumor,"
Thomas Boehm explains. "In one approach, Sakaguchi is attempting to
convert tumor resident regulatory T cells into conventional T-cells, which then
switch sides and participate in attack. If this strategy is successful, an
essential component of the body´s peacekeeping force will be converted into an
aggressor directed at the malignant tissue ".
At present, various strategies
for the treatment of autoimmune diseases and cancer based on the manipulation
of regulatory T cells are being evaluated, although these approaches are still
in an early phase of clinical development. As with many groundbreaking ideas,
therapeutic application requires a long period of painstaking work before they
can be offered to patients.
Short
biography of Professor Shimon Sakaguchi
Professor Shimon Sakaguchi, M.D.
(69) is a medical doctor. He studied medicine at Kyoto University in Japan,
then moved to Johns Hopkins University in Baltimore as a post-doctoral fellow
and then to Stanford University in California. In 1989 he became an
"Assistant Professor" at the Scripps Research Institute in La Jolla.
In 1991, Sakaguchi returned to Japan and worked at the Tokyo Metropolitan
Institute of Gerontology and later at the Institute for Frontier Medical
Sciences at Kyoto University, where he was temporarily director. Since 2011, he
has been working at Osaka University. In 2012 he became a Foreign Member of the
American National Academy of Sciences and in 2017 the Japanese government
appointed him "Person of Cultural Merit". Sakaguchi has received many
awards, including the William B. Coley Award from the Cancer Research
Institute, the Keio Medical Science Prize, the Canada Gairdner International
Award and the Crafoord Prize. Last year he was awarded the "German
Immunology Prize 2019".
The Paul Ehrlich and Ludwig
Darmstaedter Prize
The Paul Ehrlich and Ludwig Darmstaedter Prize
is traditionally awarded on Paul Ehrlich's birthday, March 14, in the
Paulskirche, Frankfurt. It honors scientists who have made significant
contributions in Paul Ehrlich's field of research, in particular immunology,
cancer research, microbiology, and chemotherapy. The Prize, which has been
awarded since 1952, is financed by the German Federal Ministry of Health, the
German association of research-based pharmaceutical company vfa e.V. and
specially earmarked donations from the following companies, foundations and
organizations: Christa Verhein Stiftung, Else Kröner-Fresenius-Stiftung,
Sanofi-Aventis Deutschland GmbH, C.H. Boehringer Sohn AG & Co. KG, Biotest AG, Hans und Wolfgang
Schleussner-Stiftung, Fresenius SE & Co. KGaA, F. Hoffmann-LaRoche Ltd.,
Grünenthal Group, Janssen-Cilag GmbH, Merck KGaA, Bayer AG, Holtzbrinck
Publishing Group, AbbVie Deutschland GmbH & Co. KG, die
Baden-Württembergische Bank, B. Metzler seel. Sohn & Co. and Goethe-Universität. The prizewinner is selected by the Scientific Council
of the Paul Ehrlich Foundation.
The
Paul Ehrlich Foundation
The
Paul Ehrlich Foundation is a legally dependent foundation which is managed in a
fiduciary capacity by the Association of Friends and Sponsors of the Goethe
University, Frankfurt. The Honorary Chairman of the Foundation, which was
established by Hedwig Ehrlich in 1929, is Professor Dr. Katja Becker, president
of the German Research Foundation, who also appoints the elected members of the
Scientific Council and the Board of Trustees. The Chairman of the Scientific
Council is Professor Thomas Boehm, Managing Director at the Max Planck
Institute of Immunobiology and Epigenetics in Freiburg, the Chair of the Board
of Trustees is Professor Dr. Jochen Maas, Head of Research and Development and
Member of the Management Board, Sanofi-Aventis Deutschland GmbH. Professor
Wilhelm Bender, in his function as Chair of the Association of Friends and Sponsors of the
51ÁÔÆæ, is Member of the Scientific Council. The President of the 51ÁÔÆæ is at the same time a member of
the Board of Trustees.
Further
information
You can obtain selected publications, the list of publications and a
photograph of the laureate from Dr. Hildegard Kaulen, phone: +49 (0)6122/52718,
email: h.k@kaulen-wissenschaft.de and at